All In Biotech

Drug Trial Radar · NCT03677973

A Study to Investigate the Safety of AB680 in Healthy Volunteers

A Double-Blind, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB680 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: May 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Oct 16, 2018

Primary completion

Aug 19, 2019

Study completion Aug 19, 2019

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, placebo-controlled, single- and multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetic profile of AB680 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • AB680Drug

    AB680 is a Cluster of Differentiation (CD)73 Inhibitor

  • PlaceboOther

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs).Time frame: From First Dose Date to 15 Days After the Last Dose of AB680.
  2. AB680 Peak Plasma Concentration (Cmax)Time frame: From First Dose Date to 15 Days After the Last Dose of AB680.
  3. AB680 Time of Peak Concentration (Tmax)Time frame: From First Dose Date to 15 Days After the Last Dose of AB680.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Melbourne, VIC

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.